Transformation of adenocarcinoma to squamous cell carcinoma as a source of EGFR-TKI resistance: A case report and literature review

In general, non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations respond to tyrosine kinase inhibitors (TKIs). However, most patients experience resistance within 1-2 years after treatment. The histological explanation for the acquired resistance is that maligna...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2022-09, Vol.12
Main Authors: Xi, Yun-Zhu, Xie, Li, Tan, Xiao-Wu, Zeng, Sai-Li
Format: Article
Language:English
Subjects:
adenocarcinoma
epidermal growth factor receptor
Oncology
squamous cell carcinoma
transformation
tyrosine kinase inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In general, non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations respond to tyrosine kinase inhibitors (TKIs). However, most patients experience resistance within 1-2 years after treatment. The histological explanation for the acquired resistance is that malignant transformation occurs during cancer treatment. To date, the transformation from adenocarcinoma to squamous cell carcinoma associated with EGFR-TKI use remains poorly reported. We report a case of stage IV lung adenocarcinoma with EGFR mutations that converted to squamous cell carcinoma due to long-term administration of EGFR-TKIs. This report strengthens histological evolution as a source of acquired drug resistance.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.942084